← Back to patent-cliff list
Glycopyrronium bromide/Neostigmine metilsulfate
Tier C — Watch / tradeGlycopyrronium bromide/Neostigmine metilsulfate
Sintetica Gmbh
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs, AChE
Brand：Prevduo, Novistig
Indications (approved)：Neuromuscular blockade
Regional status
US
Withdrawn
EU
Approved
2020-09-23
China
Phase I
2025-07-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Glycopyrronium bromide/Neostigmine metilsulfate?
Approved indications include: Neuromuscular blockade.
When does the Glycopyrronium bromide/Neostigmine metilsulfate patent expire?
No public expiry year is available for Glycopyrronium bromide/Neostigmine metilsulfate yet; this page updates once verified.
How do I get a quote for Glycopyrronium bromide/Neostigmine metilsulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27